Skip to main content
. 2011 Jan;89(1):3–10. doi: 10.1189/jlb.0510281

Figure 2. Intratracheal administration of the δ-PKC TAT peptide inhibitor decreases 2CLP-mediated elevations of the chemokines CINC-1 and MIP-2 in the lung and plasma.

Figure 2.

(A) BALF was collected by instilling and withdrawing 1.5 ml sterile PBS three times from the lungs via an intratracheal cannula (24 h post-2CLP or SO). CINC-1 and MIP-2 levels are expressed as mean ± se (pg/ml; n=8–14). *P < 0.01 SO versus 2CLP + PBS; **P < 0.01 2CLP + PBS versus 2CLP + δ-PKC TAT. (B) Plasma CINC-1 and MIP-2 levels are expressed as mean ± se (n=8–14). *P < 0.01 SO versus 2CLP + PBS; **P < 0.01 2CLP + PBS versus 2CLP + δ-PKC TAT.